procainamide has been researched along with Myelodysplastic Syndromes in 1 studies
Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, YS | 1 |
| Shaw, AY | 1 |
| Wang, SG | 1 |
| Hsu, CC | 1 |
| Teng, IW | 1 |
| Tseng, MJ | 1 |
| Huang, TH | 1 |
| Chen, CS | 1 |
| Leu, YW | 1 |
| Hsiao, SH | 1 |
1 other study available for procainamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Identification of novel DNA methylation inhibitors via a two-component reporter gene system.
Topics: Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Cell Line, Tumor; DNA Methylation; Drug Scr | 2011 |